SRRK
Scholar Rock Holding
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 0
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About SRRK
Scholar Rock Holding Corporation
A clinical-stage biopharmaceutical company focused on innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role
301 Binney Street, 3rd Floor, Cambridge, MA 02142
--
Scholar Rock Holding Corporation was founded in Delaware in 2017. The company is a biopharmaceutical company focused on the discovery and development of innovative drugs for the treatment of serious diseases in which protein growth factor signaling plays an important role. As a global leader in transforming growth factor β superfamily biology, the company's new understanding of the molecular mechanism of growth factor activation enables it to develop a proprietary platform for the discovery and development of locally and selectively targeted growth factor precursors or potential forms of monoclonal antibodies. Based on this proprietary and scalable technology platform, the company is building a growing portfolio of novel product candidates designed to transform the lives of patients with multiple serious diseases, including neuromuscular diseases, cancer, fibrosis and iron-limiting anemia.
Company Financials
EPS
SRRK has released its 2024 Q4 earnings. EPS was reported at -2.47, versus the expected -0.63, missing expectations. The chart below visualizes how SRRK has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
